Organogenesis (NASDAQ:ORGO) Shares Gap Up on Better-Than-Expected Earnings

Organogenesis (NASDAQ:ORGO) shares gapped up before the market opened on Friday after the company announced better than expected quarterly earnings. The stock had previously closed at $3.89, but opened at $5.11. Organogenesis shares last traded at $5.1410, with a volume of 5,105,479 shares trading hands.

The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.07 by $0.11. The firm had revenue of $150.86 million for the quarter, compared to analyst estimates of $134.10 million. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.05%. Organogenesis has set its FY 2025 guidance at EPS.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Wall Street Zen upgraded Organogenesis from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Cantor Fitzgerald increased their target price on Organogenesis from $7.00 to $9.00 and gave the stock an “overweight” rating in a research note on Friday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Organogenesis in a research report on Wednesday, October 8th. Finally, BTIG Research reiterated a “buy” rating and set a $7.00 price target on shares of Organogenesis in a research note on Friday, September 26th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Organogenesis currently has a consensus rating of “Hold” and a consensus target price of $7.33.

Hedge Funds Weigh In On Organogenesis

Institutional investors and hedge funds have recently modified their holdings of the company. First Light Asset Management LLC purchased a new position in shares of Organogenesis in the 2nd quarter valued at about $24,804,000. Assenagon Asset Management S.A. boosted its stake in Organogenesis by 69.9% in the third quarter. Assenagon Asset Management S.A. now owns 4,854,942 shares of the company’s stock valued at $20,488,000 after acquiring an additional 1,997,038 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Organogenesis by 23.4% during the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock worth $19,144,000 after purchasing an additional 841,618 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Organogenesis by 3.9% during the second quarter. Acadian Asset Management LLC now owns 2,424,363 shares of the company’s stock worth $8,862,000 after purchasing an additional 91,118 shares during the last quarter. Finally, Driehaus Capital Management LLC acquired a new stake in shares of Organogenesis during the first quarter worth about $7,756,000. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Trading Up 44.7%

The company has a fifty day moving average price of $4.43 and a two-hundred day moving average price of $4.19. The firm has a market capitalization of $714.22 million, a PE ratio of -46.92 and a beta of 1.68.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.